ライフサイエンスコーパス: transdermal

1 N = 34) or testosterone (three doses of 10 g transdermal 1% testosterone gel over 48 hours, N = 41) t

2 Transdermal 17B-estradiol plus cyclic progestin was asso

3 al (N=12) received open-label treatment with transdermal 17beta-estradiol (100 micro g/day) for 4 wee

4 ated equine estrogens (o-CEE), 0.45 mg/d, or transdermal 17beta-estradiol (t-E2), 50 mcg/d, each with

5 n difference, -16.8; 95% CI, -23.4 to -10.2; transdermal 17beta-estradiol, 6 trials: pooled weighted

6 xposures, it is important to consider direct transdermal absorption from air.

7 showed that CAGE was effective in enhancing transdermal absorption of NOB, compared to other penetra

8 Moreover, transdermal administration of GTN attenuated tumor growt

9 effectively prevented by i.v. injection and transdermal administration of Hph-1-ctCTLA-4.

10 <0.05) improvement in bioavailability, after transdermal administration of nanotransfersomal ATV gel

11 e studied the effect of 3 days of continuous transdermal administration of nitroglycerin (NTG) (10 mg

12 Thus, transdermal administration of NOB using CAGE was shown t

13 Three days of continuous transdermal administration of NTG was accompanied by inc

14 ormoxia and sympathetic inhibition (via 48 h transdermal administration of the centrally acting alpha

15 Finally, transdermal administration of the nitric oxide (NO) mime

16 ess excellent physicochemical properties for transdermal administration.

17 n, thus supporting painless and non-invasive transdermal administration.

18 ntial application of this device in wearable transdermal alcohol measurements.

19 tionally being required to wear a continuous transdermal alcohol monitoring anklet.

20 tudy provided experience in using continuous transdermal alcohol monitors in an experimental context,

21 o design a research project using continuous transdermal alcohol monitors with ex-offenders who recog

22 were administered to C57BL/6 female mice via transdermal alone and in combination with the oral route

23 rogress toward continuous minimally invasive transdermal analysis of drugs of abuse and nerve agents

24 round 1.5 times tumor suppression in case of transdermal and combination of routes at the end of 15th

25 Emerging antimicrobial transdermal and ocular microneedle patches have become p

26 Although recent advances in transdermal and oral delivery have been significant, bot

27 Here we report in vivo noninvasive transdermal and transcranial imaging of the structure an

28 ood pressure, as well as the nonoral routes (transdermal and vaginal).

29 significantly increased separately for oral, transdermal, and implanted oestrogen-only formulations (

30 northern Thailand were randomized to receive transdermal androgen (AndroGel; Besins Healthcare, Bruss

31 Transdermal androgen was effective in relieving symptoms

32 These results demonstrate that systemic or transdermal application of a cell-permeable form of the

33 rs, as drug delivery systems for topical and transdermal applications.

34 e wearable TENGs, it successfully realizes a transdermal biomolecule delivery with an over threefold

35 work a novel self-powered microneedle-based transdermal biosensor for pain-free high-accuracy real-t

36 The proposed transdermal biosensor makes use of an array of silicon-d

37 Our findings indicate that the proposed transdermal combined CAP and ICB therapy can inhibit the

38 icipants were randomly assigned to receive a transdermal contraceptive patch (n = 812) vs an OC (n =

39 opment and preclinical testing of patches of transdermal core-shell microneedles-which were fabricate

40 of siRNA may overcome certain limitations to transdermal delivery (specifically keratinocyte uptake)

41 um lauryl sulfate enhances the efficiency of transdermal delivery and delays the recovery of the barr

42 may serve as promising means for controlled transdermal delivery and targeted intradermal administra

43 ng with the development of novel vehicles of transdermal delivery and the use of anesthetics in combi

44 ial that has been reported to be a promising transdermal delivery approach.

45 able smartphone-controlled, battery operated transdermal delivery devices that can be coupled to remo

46 Transdermal delivery is an advantageous method of drug a

47 and third-generation enhancement strategies, transdermal delivery is poised to significantly increase

48 carbonyl-5-fluorouracil, is known to enhance transdermal delivery of 5-fluorouracil, an important sys

49 ression in exploitation of MN for successful transdermal delivery of a much wider range of drugs.

50 show promise for the electrically controlled transdermal delivery of biomacromolecules in a simple, o

51 Thus, transdermal delivery of DFO improves tissue perfusion an

52 These findings suggest that transdermal delivery of DFO provides a targeted means to

53 ulcer model in diabetic mice, we found that transdermal delivery of DFO significantly improved wound

54 drogel-forming microneedle arrays facilitate transdermal delivery of drugs by penetrating the outer l

55 tablished as one of the methods of enhancing transdermal delivery of drugs.

56 sential for chemical exposure assessment and transdermal delivery of drugs.

57 emonstrate for the first time the concurrent transdermal delivery of erlotinib and IL36alpha siRNA as

58 The enhanced co-transdermal delivery of erlotinib and IL36alpha siRNA by

59 Week-long transdermal delivery of high-dose hydrophilic drugs rema

60 Transdermal delivery of hydrophilic drugs is challenging

61 irst time that high-dose week-long sustained transdermal delivery of hydrophilic drugs was achieved v

62 py integrated with microneedles (MN) for the transdermal delivery of ICB.

63 demonstrated improved immune responses after transdermal delivery of inactivated influenza virus with

64 Transdermal delivery of large hydrophilic molecules is a

65 Transdermal delivery of LNG from earring patches across

66 Traditional patches are most successful in transdermal delivery of low-dose hydrophobic drugs.

67 In the present study, we investigated the transdermal delivery of NOB using choline and geranic ac

68 Microneedles (MNs) allow transdermal delivery of otherwise skin-impermeable drugs

69 (AFL) to assist 3-day to week-long sustained transdermal delivery of powder hydrophilic drugs in muri

70 bioavailability and poor skin permeability, transdermal delivery of protein therapeutics poses a sig

71 c acid (CAGE), have been used to enhance the transdermal delivery of several small and large molecule

72 Microneedles (MNs) allow transdermal delivery of skin-impermeable drugs by creati

73 effect of MN heigth and MN density upon the transdermal delivery of small hydrophilic compounds (the

74 m of this investigation was to visualize the transdermal delivery of sulforhodamine B (SRB), a fluore

75 les to promote skin rejuvenation or increase transdermal delivery of topical medications.

76 The benefits of transdermal delivery over the oral route to combat such

77 Indeed in in vitro transdermal delivery studies, approximately 33mg (90%) o

78 expectedly, prophylactic application of this transdermal delivery system also prevented diabetic ulce

79 ide using a dissolvable microstructure-based transdermal delivery system.

80 nicotine BA from two, matrix-type, nicotine transdermal delivery systems (TDS).

81 for assuring the quality and performance of transdermal delivery systems and topical patches (collec

82 First-generation transdermal delivery systems have continued their steady

83 e investigations revealed that the extent of transdermal delivery was dependent upon the design of th

84 may broaden the range of drugs suitable for transdermal delivery, as well as enabling the rate of de

85 s potential in the MN mediated iontophoretic transdermal delivery.

86 rm of an active therapeutic agent to enhance transdermal delivery.

87 pid to disrupt the skin barrier for enhanced transdermal delivery.

88 of CPEs that can aid the design of optimized transdermal, dermatological, and cosmetic formulations i

89 cers (CPEs) are present in a large number of transdermal, dermatological, and cosmetic products to ai

90 r approach for improving drug penetration of transdermal devices and increasing cellular uptake of na

91 drug delivery systems, such as implants and transdermal devices, are promising strategies that are b

92 s administered alternatively, beginning with transdermal dose.

93 of combination of routes, mice were given 5 transdermal doses and 5 oral doses administered alternat

94 ne to rationally design better enhancers for transdermal drug and vaccine delivery by electroporation

95 ly shown to enable skin permeabilisation for transdermal drug and vaccine delivery, by sequentially a

96 provide insight into the development of new transdermal drug carriers to treat a variety of skin dis

97 By any measure, transdermal drug delivery (TDD) is a successful controll

98 density led to an increase in the extent of transdermal drug delivery achieved 6h after MN applicati

99 imally-invasive fashion and achieve enhanced transdermal drug delivery and "targeted" intradermal vac

100 s outlining the design principles of ILs for transdermal drug delivery are still lacking.

101 reveal that the potency of ILs in enhancing transdermal drug delivery correlates inversely with the

102 ployed as the active element of a switchable transdermal drug delivery device that can facilitate mor

103 highlighted the importance of MN design for transdermal drug delivery enhancement, to date, there ha

104 The widespread adoption of transdermal drug delivery has been limited by the barrie

105 Transdermal drug delivery has made an important contribu

106 Transdermal drug delivery is limited by the barrier prop

107 Although transdermal drug delivery is more attractive than inject

108 icant difference in absorption of drugs from transdermal drug delivery is observed in different age g

109 onic liquids as an effective and noninvasive transdermal drug delivery method.

110 of hydrogel-forming microneedle arrays as a transdermal drug delivery platform for ESK and supports

111 To improve HIF-1alpha activity we designed a transdermal drug delivery system (TDDS) containing the F

112 d whether topical DFO administration using a transdermal drug delivery system prior to and immediatel

113 C) for drug-in-adhesive (DIA) type estradiol transdermal drug delivery systems (TDDS).

114 Transdermal drug delivery systems as films not only avoi

115 The therapeutic efficacy of conventional transdermal drug delivery systems is often limited becau

116 Transdermal drug delivery using spring-powered jet injec

117 ultrasound presents an attractive method for transdermal drug delivery.

118 etration enhancers are often used to enhance transdermal drug delivery.

119 um height resulted in the greatest extent of transdermal drug delivery.

120 rs playing a significant role in US-mediated transdermal drug delivery.

121 he safety of topical products and to advance transdermal drug delivery.

122 idrug resistance protein known to facilitate transdermal drug delivery.

123 , will aid in the design and optimization of transdermal drug delivery.

124 iers is presented, with special attention to transdermal drug delivery.

125 ression with a chromogenic reporter, mapping transdermal drug distributions without histological sect

126 ermore, a self-powered on-skin iontophoretic transdermal drug-delivery system is developed as an on-s

127 Transdermal E(2) had no effect on CRP or IGF-1 levels.

128 Neither transdermal E(2) nor oral CEE had any effects on the pla

129 We investigated the effects of this transdermal electrical neurosignaling (TEN) method on sy

130 Intravesical or transdermal electrical stimulation, sacral nerve stimula

131 enhancers (CPEs), especially surfactants, in transdermal enhancement has been investigated extensivel

132 Because the effects of transdermal ERT are larger than those of oral ERT, the r

133 n normotensive postmenopausal women, chronic transdermal ERT decreases SND without augmenting arteria

134 After 8 weeks of transdermal ERT, the basal rate of SND decreased by 30%

135 fter 3 weeks of open-label administration of transdermal estradiol (100 microg/d), participants were

136 ty were measured before and after 8 weeks of transdermal estradiol (200 microgram/d), oral conjugated

137 factor-alpha before and after eight weeks of transdermal estradiol (E(2)) (100 microg/day), oral conj

138 th, 211 women randomized to receive 50 mug/d transdermal estradiol (t-E2) plus 200 mg/d m-P for the f

139 ily oral conjugated equine estrogen (CEE) or transdermal estradiol alters hemostatic factors in postm

140 ly different from the change observed in the transdermal estradiol group (p < 0.05).

141 Transdermal estradiol had no significant effect on lipid

142 Transdermal estradiol has been associated with virtually

143 Transdermal estradiol replacement is an effective treatm

144 itor-1 antigen declined in both oral CEE and transdermal estradiol users, but did not achieve statist

145 o receive daily oral CEE, 0.625 mg (n = 21); transdermal estradiol, 0.1 mg/day (n = 7); or oral place

146 taneously 3 times/wk) + sex steroids (women: transdermal estradiol, 100 micro g/d, plus oral medroxyp

147 as known thromboembolic risk, and lower-dose transdermal estrogen formulations are preferred over hig

148 ting of 103 women who were receiving oral or transdermal estrogen-replacement therapy (44 of whom wer

149 In postmenopausal women, oral but not transdermal ET increased CRP by a first-pass hepatic eff

150 When the device was fed with transdermal extracts, containing only 30 muM of glucose,

151 Therefore, we tested the effects of transdermal fentanyl (TDF) in patients with moderate-to-

152 iven by 73.7% of patients (233/316) who used transdermal fentanyl PCA and 76.9% of patients (246/320)

153 reasing patient compliance and expanding the transdermal field to a wider variety of clinical conditi

154 in vivo in a subcutaneous mouse model using transdermal fluorescent imaging to monitor degradation.

155 ology for evaluating transient, finite dose, transdermal flux data collected using traditional experi

156 d with glucose (180 Da) and inulin (5000 Da) transdermal flux experiments, which showed greater perme

157 ance, by one to two orders of magnitude, the transdermal flux.

158 This investigation shows that the transdermal fluxes of highly lipophilic compounds can be

159 linicians consider intramuscular rather than transdermal formulations when initiating testosterone tr

160 enteral polymeric microspheres/implants, and transdermal formulations), and briefly summarizes the kn

161 then randomly assigned to 14 weeks of daily transdermal gel that contained 10-g testosterone for 70

162 ial, the authors administered a testosterone transdermal gel to men aged 30-65 who had refractory dep

163 luorescence affinity hollow fiber sensor for transdermal glucose monitoring is demonstrated.

164 of these aggregates for use in physiological transdermal glucose monitoring, either for implantable s

165 In naive male Vglut1-ChR2 mice, transdermal hindpaw photostimulation evoked withdrawal b

166 Crucially, oral but not transdermal hormone-replacement therapy increases activa

167 benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chron

168 nogen, factor VII, and PAI (less change with transdermal HRT) and antithrombin III.

169 We found that transdermal iontophoresis of protons consistently caused

170 gue-Dawley rats to assess the feasibility of transdermal iontophoretic delivery in vivo, of a lipophi

171 tecting group that can be easily removed via transdermal light exposure to render the peptide fully a

172 automatic dynamic permeation tests mimicking transdermal measurements in Franz-cell configurations.

173 ti-OVA IgG antibody levels compared to other transdermal methods.

174 eral other modified delivery systems such as transdermal microneedle patches, in situ forming injecta

175 This self-adherent transdermal MN platform can be applied to a variety of p

176 es and blood, facilitating their use for the transdermal monitoring of cyanide for mammalian safeguar

177 We engineered a transdermal neuromodulation approach that targets periph

178 at were identical, except that smokers had a transdermal nicotine (21 mg) or placebo patch placed bef

179 Abstinence rates for the transdermal nicotine and nicotine nasal spray groups wer

180 The transdermal nicotine delivery device was able to success

181 a nicotine formulation to obtain switchable transdermal nicotine delivery rates on human skin (in vi

182 ng cessation is to remotely program variable transdermal nicotine delivery rates, with inputs from co

183 (CNT) membrane device has been developed for transdermal nicotine delivery that can be programmed to

184 Transdermal nicotine for 24 weeks increased biochemicall

185 ng smokers of European ancestry treated with transdermal nicotine in two independent cohorts.

186 were scanned under each condition wearing a transdermal nicotine or placebo patch.

187 fferent days under each condition, wearing a transdermal nicotine or placebo patch.

188 All subjects received 8 weeks of a transdermal nicotine patch, five group counseling sessio

189 the pharmaceutical company could market its transdermal nicotine patch.

190 Nicotine replacement therapy in the form of transdermal nicotine patches and nicotine gums combined

191 Attention task performance was improved by transdermal nicotine relative to placebo, with intermedi

192 Transdermal nicotine replacement improved task performan

193 nence after a lapse compared with 8 weeks of transdermal nicotine therapy.

194 The failure of transdermal nicotine to alter reward-related functional

195 white achieved higher abstinence rates with transdermal nicotine, whereas smokers who were highly de

196 eeks of therapy with nicotine nasal spray or transdermal nicotine.

197 ining individualized doses of sublingual and transdermal nitrates, low-dose oral hydralazine for 48 h

198 Application of transdermal nitroglycerin patches or treatment with L-ar

199 these malaria-specific nanobubbles provided transdermal noninvasive and rapid detection of a malaria

200 Neither transdermal nor oral ERT had any effects on baroreflex s

201 ced by IV NTG, demonstrating the efficacy of transdermal NTG as an alternative form of NTG delivery f

202 Transdermal NTG patches elicited a late PC effect that w

203 After 1 month of transdermal oestradiol replacement in these women, the n

204 l tablets, buccal tablets, sublingual spray, transdermal ointment, and transdermal patch, as well as

205 nonobstetric sample; used oral, topical, or transdermal opioids; and focused on treatment for chroni

206 eater or lesser abstinence rates with either transdermal or nasal spray nicotine.

207 Transdermal or vaginal estrogen resulted in inconsistent

208 livery of biologics, including subcutaneous, transdermal, oral, inhalation, nasal and buccal routes.

209 Transdermal OVA doses of up to 1mug were achieved in a s

210 on to sustained release oral medication, the transdermal patch and the intravaginal route are startin

211 nicotine (TNP; n=37) or placebo (PBO; n=43) transdermal patch following overnight abstinence complet

212 introduce pharmaceutical jewelry, in which a transdermal patch is incorporated into jewelry worn on s

213 randomization to 5 mg testosterone daily by transdermal patch or matching placebo for 12 weeks, in a

214 st that can be administered once daily or by transdermal patch seems to be a reasonable option to con

215 Recent additions include a contraceptive transdermal patch, a hormone-releasing intravaginal ring

216 replacement group received a 21-mg nicotine transdermal patch, and those in the placebo group were t

217 sublingual spray, transdermal ointment, and transdermal patch, as well as intravenous formulations.

218 Here, we show that a single removable transdermal patch, bearing microneedles loaded with insu

219 raceptive methods (oral contraceptive pills, transdermal patch, contraceptive vaginal ring, and depot

220 A shorter acting contraceptive option is the transdermal patch.

221 r systemic delivery of macromolecules from a transdermal patch.

222 st that can be administered once daily or by transdermal patch.

223 delivery that are inspired by the design of transdermal patches and demonstrate their capabilities i

224 To demonstrate the approach, we incorporated transdermal patches containing the contraceptive hormone

225 ording to DSM-IV, were randomized to receive transdermal patches of 17beta-estradiol (100 microgram)

226 been fabricated and envisioned for use with transdermal patches or infusion pumps to achieve painles

227 up to 8-weeks treatment with NRT (15 mg/16 h transdermal patches) or identically packaged and visuall

228 stems that make use of micro/nano-particles, transdermal patches, inhalers, drug reservoir implants a

229 hormonal contraceptive systems that include transdermal patches, intravaginal rings (IVRs), intraute

230 To address low permeability in transdermal patches, permeation enhancers such as alkano

231 For transdermal patches, the corresponding relative risks we

232 skin by using a fluorescent dye to probe the transdermal pathways of the enhancer.

233 complex structure of the stratum corneum on transdermal penetration is not yet fully described by ex

234 Visualization of transdermal permeant pathways is necessary to substantia

235 The effect of vehicle mixtures on transdermal permeation has been studied using transient

236 teral transport on skin, combined with a low transdermal permeation rate, may thus be seen to be a ke

237 Transdermal photo-cross-linking of acrylated biopolymers

238 neous electroreceptors detect changes in the transdermal potential (TDP) as the fish interact with co

239 quency, weak electric field and perceive the transdermal potential modulations caused by a nearby tar

240 ht use the spectral content of the perceived transdermal potential modulations to classify the living

241 Over the last 30+ years, a steady flux of transdermal products have received regulatory approval a

242 Here, we present a new approach for transdermal protein delivery using bullet-shaped double-

243 in three phases: pretreatment (Phase A1), on transdermal rotigotine for 7-11 days (Phase B) and post-

244 ministration of NTG via either the IV or the transdermal route elicits a robust protective effect aga

245 rogen-replacement therapy, primarily via the transdermal route, increases BMD in adolescents, althoug

246 biologically active macromolecules, via the transdermal route.

247 m encapsulating ATV for its delivery via the transdermal route.

248 pproaches (e.g., oral, nasal, pulmonary, and transdermal routes) for protein delivery.

249 A transdermal SARM has a potential to have therapeutic ben

250 us tear production was inhibited by applying transdermal scopolamine (scop) patches to the depilated

251 benefit from long-acting antiemetics such as transdermal scopolamine, aprepitant, and/or palonosetron

252 Transdermal selegiline (20 mg applied once daily by mean

253 e disorder were randomly assigned to receive transdermal selegiline (20 mg applied once daily by mean

254 hors investigated the efficacy and safety of transdermal selegiline in adult outpatients with major d

255 ty for high doses of oral selegiline and for transdermal selegiline suggesting that when plasma level

256 erved after 6 weeks in patients treated with transdermal selegiline than in those given placebo accor

257 Mice were rendered hazelnut allergic by a transdermal sensitization/oral elicitation protocol.

258 to improve the stability and reliability of transdermal sensors, due to the reduction of the detrime

259 g deeply penetrating near-infrared light for transdermal stiffness modulation, enabling external cont

260 f insulin, including oral, nasal, pulmonary, transdermal, subcutaneous and closed-loop insulin delive

261 y (1950-1980) focused on developing oral and transdermal sustained release systems and establishing c

262 ) and in 3 subjects receiving the selegiline transdermal system (Emsam patch, 6 mg/day) using positro

263 ion over 10 minutes) by a patient-controlled transdermal system (n = 316).

264 While different technical aspects of transdermal system development have been discussed at va

265 he fentanyl hydrochloride patient-controlled transdermal system eliminates the need for venous access

266 An investigational PCA transdermal system using iontophoresis to deliver fentan

267 , which were more common with the selegiline transdermal system.

268 (ii) nanoparticle-based cancer drugs, (iii) transdermal systems, (iv) oral drug delivery systems, (v

269 ach for the development and manufacturing of transdermal systems.

270 Transdermal (TD) delivery provides an excellent alternat

271 blunting the clinical utility of this unique transdermal technique.

272 Transdermal testosterone alone has not been shown to imp

273 ght to determine whether adjunctive low-dose transdermal testosterone improves depression symptom sev

274 We evaluated the effects of transdermal testosterone in women who had impaired sexua

275 Adjunctive transdermal testosterone, although well tolerated, was n

276 In vitro transdermal tests using a Franz diffusion cell showed th

277 We demonstrate that non-invasive, transdermal time-regulated activation of cell-adhesive R

278 Ultrasound-enhanced transdermal transport is mediated by inertial cavitation

279 logy, we report a significant improvement of transdermal transport of dextrans of various molecular w

280 s a particularly important role in enhancing transdermal transport of macromolecules, thereby offerin

281 ral phospholipids, were found to enhance the transdermal transport of molecules by electroporation.

282 uired to accurately determine the changes in transdermal transport properties incurred globally, over

283 captures the relative changes in the global transdermal transport properties of the hydrophobic prob

284 The oleic-acid-induced changes in the transdermal transport properties of the model hydrophobi

285 etically derived mathematical expressions of transdermal transport to quantitatively characterize the

286 tant insight into the mechanistic changes in transdermal transport underlying the visualized changes

287 t, improvements in enhancing the efficacy of transdermal ultrasound treatments have been limited.

288 tly reported (Indoor Air 2012, 22, 356) that transdermal uptake directly from air could be comparable

289 We recently reported that transdermal uptake directly from air could be comparable

290 Transdermal uptake directly from air is a potentially im

291 Transdermal uptake models compliment in vitro and in viv

292 s used in a diffusion-based model to predict transdermal uptake of each chemical and was compared wit

293 However, transdermal uptake rates from air have not been measured

294 This study investigated transdermal uptake, directly from air, of diethyl phthal

295 s indicated that nanocup-assisted ultrasound transdermal vaccination achieved significantly (p<0.05)

296 mes tumor suppression when administered with transdermal vaccine and around 9 times tumor suppression

297 The transdermal vaccine was delivered using a metallic micro

298 o-controlled study to compare the effects of transdermal versus oral ET on CRP and inflammatory cytok

299 e results obtained suggest that the proposed transdermal vesicular system can serve as a promising al

300 The transdermal vesicular system exhibited a significant dec